Extensive evidence highlights that targeted PAH therapy improves exercise capacity, reduces PVR, and promotes pulmonary vascular remodeling through endothelin-1 inhibition, activation of the NO-cGMP pathway, and antiproliferative effects, resulting in safe occlusion (1, 9, 10). The gene discussed is EDN1; the disease is pulmonary arterial hypertension.